<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02447809</url>
  </required_header>
  <id_info>
    <org_study_id>004</org_study_id>
    <nct_id>NCT02447809</nct_id>
  </id_info>
  <brief_title>Plasma and Platelet microRNAs in Clopidogrel Low Response Patients</brief_title>
  <acronym>PPRC</acronym>
  <official_title>The Association Between Plasma or Platelet microRNAs and Clopidogrel Low Response and Its Mechanism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Natural Science Foundation of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clopidogrel is an important anti-platelet agent.However, about 30% of the coronary artery
      disease patients presented clopidogrel low response (CLR).Previous studies showed that the
      cardiovascular event ratio of the CLR patients was 4.4 times of the normal responders.

      It is known that the plasma and platelet miRNAs are determined by different disease status
      when platelets are released from the megakaryocyte, and the platelet miRNAs can adjust the
      expressions of the platelet's receptors and proteins.The purpose of this study is to find
      multiple platelet miRNAs involved in the development of CLR, and platelet miRNAs cause CLR
      through adjusting the expressions of the key receptors and proteins in the ADP activating
      pathway and consequently reducing their responses to clopidogrel.

      The CLR will be detected by light transmission aggregometry (LTA) and vasodilator-stimulated
      phosphoprotein phosphorylation (VASP-P). Differential expressions of plasma and platelet
      miRNAs profile in CLR patients will be screened by deep sequencing and validated to
      investigate the association between plasma and platelet miRNAs profile and CLR as well as the
      patients' prognosis.The study results would serve as markers for individualized anti-platelet
      treatment, and supply new targets for the treatment of coronary artery disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multiphase, case-control study was designed to identify plasma and platelet miRNAs as
      surrogate markers for CLR .

      All patients take 300mg loading dose clopidogrel plus 100mg daily ASA and 75mg daily
      clopidogrel after admission. Patients are recruited after percutaneous coronary intervention
      (PCI). Light transmittancy aggregation (LTA) in response to 5μM ADP is to measured 5 days
      after taking the loading dose clopidogrel.Than CLR patients were selected.

      In the initial biomarker-screening stage, plasma and platelet samples from 20 CLR patients
      and 20 controls underwent Solexa sequencing to identify miRNAs that showed significant
      differences between the CLR cases and matched controls.

      Subsequently,we performed a biomarker confirmation analysis with a hydrolysis probe-based
      RT-qPCR assay to refine the number of plasma and platelet miRNAs in the CLR signature. This
      analysis was carried out in 2 phases: (a) the biomarker-selection phase, in which plasma and
      platelet samples from 20 CLR patients and 20 control individuals formed the training set, and
      (b) the biomarker-validation phase, in which plasma and platelet samples from an additional
      80 CLR patients and 80 controls formed the validation set.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The expressions of miRNAs profile</measure>
    <time_frame>5-days After recruited</time_frame>
    <description>Two pools of plasma and platelet were collected from participants separately. The total RNA of each pool was extracted by using Trizol Reagent. An initial screening of miRNAs expression was performed by Solexa sequencing. And differential expression was validated using RT-qPCR in individuals samples.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy</measure>
    <time_frame>1-month and 1-year after recruited</time_frame>
    <description>1-month and 1-year death,non-fatal myocardial infarction,ischemic stroke,revascularization and stent thrombosis(ARC definition)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Bleeding</measure>
    <time_frame>1-month and 1-year after recruited</time_frame>
    <description>1-month and 1-year minor,moderate and major bleeding</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Regular DAPT(IPA≤60%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASA and Clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular DAPT(IPA&gt;60%)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ASA and Clopidogrel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>(ASA 100mg daily and Clopidogre 75mg daily)* 12 month.</description>
    <arm_group_label>Regular DAPT(IPA≤60%)</arm_group_label>
    <arm_group_label>Regular DAPT(IPA&gt;60%)</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetylsalicylic acid (ASA)</intervention_name>
    <arm_group_label>Regular DAPT(IPA≤60%)</arm_group_label>
    <arm_group_label>Regular DAPT(IPA&gt;60%)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who receive stent implantation;

          -  Patients who take 100mg daily ASA and 75mg daily clopidogrel

          -  Patient age &gt;18 years and &lt;80 years old;

          -  Signed inform consent

        Exclusion Criteria:

          -  Allergy or intolerance to ASA,clopidogrel;

          -  Patients who are planning to take warfarin or drugs that potentially could interfere
             with the anti-platelet effects of ASA,clopidogrel.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunjian Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chunjian Li, Ph.D</last_name>
    <phone>+86-25-83718836</phone>
    <phone_ext>6018</phone_ext>
    <email>lijay@njmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hui Zhu</last_name>
    <phone>+86-25-83718836</phone>
    <phone_ext>6018</phone_ext>
    <email>zhuhui90@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fuming Zhang, M.D.</last_name>
      <phone>+86-25-83718836</phone>
      <phone_ext>6360</phone_ext>
      <email>jsphkj@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yi Chai, M.D.</last_name>
      <phone>+86-25-83718836</phone>
      <phone_ext>6360</phone_ext>
      <email>jsphkj@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001 Aug 16;345(7):494-502. Erratum in: N Engl J Med 2001 Nov 15;345(20):1506. N Engl J Med 2001 Dec 6;345(23):1716.</citation>
    <PMID>11519503</PMID>
  </reference>
  <reference>
    <citation>Siller-Matula JM, Trenk D, Schrör K, Gawaz M, Kristensen SD, Storey RF, Huber K; EPA (European Platelet Academy). Response variability to P2Y12 receptor inhibitors: expectations and reality. JACC Cardiovasc Interv. 2013 Nov;6(11):1111-28. doi: 10.1016/j.jcin.2013.06.011. Review.</citation>
    <PMID>24262612</PMID>
  </reference>
  <reference>
    <citation>Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res. 2006 Aug 1;66(15):7390-4. Review.</citation>
    <PMID>16885332</PMID>
  </reference>
  <reference>
    <citation>Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C, Shen H. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 2010 Apr 1;28(10):1721-6. doi: 10.1200/JCO.2009.24.9342. Epub 2010 Mar 1.</citation>
    <PMID>20194856</PMID>
  </reference>
  <reference>
    <citation>Clancy L, Freedman JE. New paradigms in thrombosis: novel mediators and biomarkers platelet RNA transfer. J Thromb Thrombolysis. 2014 Jan;37(1):12-6. doi: 10.1007/s11239-013-1001-1. Review.</citation>
    <PMID>24163053</PMID>
  </reference>
  <reference>
    <citation>Landry P, Plante I, Ouellet DL, Perron MP, Rousseau G, Provost P. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol. 2009 Sep;16(9):961-6. doi: 10.1038/nsmb.1651. Epub 2009 Aug 9.</citation>
    <PMID>19668211</PMID>
  </reference>
  <reference>
    <citation>Dangelmaier C, Jin J, Smith JB, Kunapuli SP. Potentiation of thromboxane A2-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway. Thromb Haemost. 2001 Feb;85(2):341-8.</citation>
    <PMID>11246558</PMID>
  </reference>
  <reference>
    <citation>Li C, Fang Z, Jiang T, Zhang Q, Liu C, Zhang C, Xiang Y. Serum microRNAs profile from genome-wide serves as a fingerprint for diagnosis of acute myocardial infarction and angina pectoris. BMC Med Genomics. 2013 May 4;6:16. doi: 10.1186/1755-8794-6-16.</citation>
    <PMID>23641832</PMID>
  </reference>
  <reference>
    <citation>Nagalla S, Shaw C, Kong X, Kondkar AA, Edelstein LC, Ma L, Chen J, McKnight GS, López JA, Yang L, Jin Y, Bray MS, Leal SM, Dong JF, Bray PF. Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood. 2011 May 12;117(19):5189-97. doi: 10.1182/blood-2010-09-299719. Epub 2011 Mar 17.</citation>
    <PMID>21415270</PMID>
  </reference>
  <reference>
    <citation>Katz MG, Fargnoli AS, Williams RD, Kendle AP, Steuerwald NM, Bridges CR. MiRNAs as potential molecular targets in heart failure. Future Cardiol. 2014 Nov;10(6):789-800. doi: 10.2217/fca.14.64. Review.</citation>
    <PMID>25495820</PMID>
  </reference>
  <reference>
    <citation>Song MA, Paradis AN, Gay MS, Shin J, Zhang L. Differential expression of microRNAs in ischemic heart disease. Drug Discov Today. 2015 Feb;20(2):223-35. doi: 10.1016/j.drudis.2014.10.004. Epub 2014 Oct 23. Review.</citation>
    <PMID>25461956</PMID>
  </reference>
  <reference>
    <citation>Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8. doi: 10.1073/pnas.0804549105. Epub 2008 Jul 28.</citation>
    <PMID>18663219</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2015</study_first_submitted>
  <study_first_submitted_qc>May 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2015</study_first_posted>
  <last_update_submitted>February 11, 2016</last_update_submitted>
  <last_update_submitted_qc>February 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Chunjian Li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>microRNA</keyword>
  <keyword>Platelet</keyword>
  <keyword>Clopidogrel low response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

